Scholarlink

Background <p>In carefully selected patients, liver transplantation (LT) has provided encouraging outcomes for unresectable biliary tract cancers (BTC), including biphenotypic (cHCC-CC), perihilar (pCC), and intrahepatic cholangiocarcinoma (iCCA). This study aimed to characterize diagnostic discrepancies, recurrence patterns, and oncologic metrics in this unique LT population.</p> Patients and Methods <p>Patients with BTC receiving LT within a single academic transplant center were included (<i>n</i> = 98 from 2007 to 2025). Survival and recurrence outcomes were analyzed by tumor histotype using Kaplan–Meier and log-rank tests. Univariate and multivariate Cox proportional hazards regression was performed.</p> Results <p>The most common transplanted subtype was pCC (<i>n</i> = 54, 55.1%), followed by cHCC-CC (<i>n</i> = 28, 28.6%) and iCCA (<i>n</i> = 16, 16.3%). Pretransplant diagnoses frequently differed from final explant pathology in 26 patients (26.5%). Recurrence occurred in 40 (40.8%) patients with a median time to recurrence of 16 months (interquartile range 1–160 months). Estimated 1-, 3-, and 5-year overall survival rates for the entire cohort were 88%, 68%, and 58%, respectively. On multivariate analysis, lymph node positivity (hazard ratio [3.27, <i>p</i> = 0.010), iCCA subtype (HR 2.94, <i>p</i> = 0.030), and explant tumor size (HR 1.22 per cm, <i>p</i> = 0.005) were independent predictors of recurrence.</p> Conclusions <p>This is, to our knowledge, the largest single-center analysis of liver transplant recipients with BTC. Lymph node positivity, iCCA subtype, and tumor size are independent predictors of recurrence following LT for BTC. Despite the diagnostic challenges and high disease recurrence, LT is a promising option for unresectable BTC when no other surgical option exists.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liver Transplantation for Unresectable Biliary Tract Cancers: Largest Single-Center Analysis of Subtype-Specific Survival and Recurrence (2007–2025)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月20日

查看全文
  • Sally Campbell,
  • Ola Ahmed,
  • Darren Cullinan,
  • Neeta Vachharajani,
  • Adeel S. Khan,
  • William C. Chapman,
  • Majella B. M. Doyle

摘要

Background

In carefully selected patients, liver transplantation (LT) has provided encouraging outcomes for unresectable biliary tract cancers (BTC), including biphenotypic (cHCC-CC), perihilar (pCC), and intrahepatic cholangiocarcinoma (iCCA). This study aimed to characterize diagnostic discrepancies, recurrence patterns, and oncologic metrics in this unique LT population.

Patients and Methods

Patients with BTC receiving LT within a single academic transplant center were included (n = 98 from 2007 to 2025). Survival and recurrence outcomes were analyzed by tumor histotype using Kaplan–Meier and log-rank tests. Univariate and multivariate Cox proportional hazards regression was performed.

Results

The most common transplanted subtype was pCC (n = 54, 55.1%), followed by cHCC-CC (n = 28, 28.6%) and iCCA (n = 16, 16.3%). Pretransplant diagnoses frequently differed from final explant pathology in 26 patients (26.5%). Recurrence occurred in 40 (40.8%) patients with a median time to recurrence of 16 months (interquartile range 1–160 months). Estimated 1-, 3-, and 5-year overall survival rates for the entire cohort were 88%, 68%, and 58%, respectively. On multivariate analysis, lymph node positivity (hazard ratio [3.27, p = 0.010), iCCA subtype (HR 2.94, p = 0.030), and explant tumor size (HR 1.22 per cm, p = 0.005) were independent predictors of recurrence.

Conclusions

This is, to our knowledge, the largest single-center analysis of liver transplant recipients with BTC. Lymph node positivity, iCCA subtype, and tumor size are independent predictors of recurrence following LT for BTC. Despite the diagnostic challenges and high disease recurrence, LT is a promising option for unresectable BTC when no other surgical option exists.